Pharmaceutical News

RSS

Multiple sclerosis researchers receive NMSS drug development grant

A $500,000 drug development grant from the National Multiple Sclerosis Society was awarded to a partnership between a multiple sclerosis research team at the Icahn School of Medicine at Mount Sinai and Karyopharm Therapeutics Inc., a clinical stage pharmaceutical company. Dr. Patrizia Casaccia, MD, PhD, Professor in the Departments of Neuroscience and Genetics and Genomics, at Icahn School of Medicine at Mount Sinai, will be the academic lead.

21 Nov 2013

Enhancing the NMDA glutamate receptor causes antidepressant-like effects

Thirteen years ago, an article in this journal first reported that the anesthetic medication, ketamine, showed evidence of producing rapid antidepressant effects in depressed patients who had not responded to prior treatments. Ketamine works by blocking one of the targets for the neurotransmitter glutamate in the brain, the N-methyl-D-aspartate (NMDA) glutamate receptor.

20 Nov 2013

First look at The Endocrine Society's Performance-Enhancing Drugs Scientific Statement

Performance-enhancing drugs are synonymous with the names of elite athletes including Alex Rodriguez and Ryan Braun. In reality, major league athletes make up only a fraction of the nation's 3 million performance-enhancing drug users. As thousands of PED users age into their 50s, the long-term health effects are expected to become visible for the first time.

20 Nov 2013

Adverse events linked with HPV vaccine appear to be related with media coverage

The number of adverse events associated with the HPV vaccine reported to the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) appeared to be related to media coverage and online controversy about the vaccine, finds a study in the Journal of Adolescent Health.

20 Nov 2013

Study finds resveratrol in colored vegetables, fruits may block effects of methamphetamine

Studies have shown that resveratrol, a natural compound found in colored vegetables, fruits and especially grapes, may minimize the impact of Parkinson's disease, stroke and Alzheimer's disease in those who maintain healthy diets or who regularly take resveratrol supplements.

20 Nov 2013

mTOR protein: A key mediator of antidepressant effects of ketamine

Two years ago, mammalian target of rapamycin or mTOR, a signaling protein, was identified as a key mediator of the antidepressant effects of ketamine, the first rapidly acting antidepressant medication to be identified.

20 Nov 2013

UCP1 protein helps fight against obesity

The uncoupling Protein 1 (UCP1) is found exclusively in brown adipose tissue. Until some years ago it was thought that only babies and hibernating animals had brown adipose tissue, but since then it also has been found in adults, so UCP1 could be useful in the fight against obesity.

20 Nov 2013

U-M researchers collaborate with MDCH to evaluate statewide influenza vaccination reminder campaign

A new University of Michigan study found that the state immunization registry - the public health database that tracks vaccinations- can be an effective tool to encourage influenza vaccinations during a pandemic.

19 Nov 2013

Long-term use of PDE3 inhibitors can lead to increased risk for sudden cardiac death

Drugs known as PDE3 inhibitors save many lives by helping failing hearts do a better job of pumping blood. But those same medications come with a sometimes deadly cost when taken for long periods: an increased risk for sudden cardiac death.

19 Nov 2013

Treating traumatic brain-injured patients with anticoagulant decreases risk of dangerous clots

Researchers from the University of Missouri School of Medicine have found that a new protocol that uses preventive blood-thinning medication in the treatment of patients with traumatic brain injuries reduces the risk of patients developing life-threatening blood clots without increasing the risk of bleeding inside the brain.

19 Nov 2013

Research shows oral contraceptive use over three years could be a risk factor for glaucoma

Research presented today, at the 117th Annual Meeting of the American Academy of Ophthalmology in New Orleans, has found that women who have taken oral contraceptives for three or more years are twice as likely to suffer from glaucoma, one of the leading causes of blindness which affects nearly 60 million worldwide. The researchers caution gynecologists and ophthalmologists to be aware of the fact that oral contraceptives might play a role in glaucomatous diseases, and inform patients to have their eyes screened for glaucoma if they also have other risk factors.

19 Nov 2013

Vismodegib drug does not offer added benefits for patients with BCC

The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients with two forms of basal cell carcinoma: symptomatic metastatic BCC and locally advanced BCC inappropriate for surgery or radiotherapy.

19 Nov 2013

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration.

18 Nov 2013

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.

18 Nov 2013

Entire structure of health-care delivery needs to be re-engineered to address threat of antibiotic resistance

The entire structure of health-care delivery for effective antibiotics – from research and development, to distribution and rational use – needs to be re-engineered to address the looming global threat of antibiotic resistance, say the authors of a new report, published today [Sunday 17 November] in The Lancet Infectious Diseases, ahead of European Antibiotic Awareness Day, and the US Centers for Disease Control and Prevention (CDC) ‘Get Smart About Antibiotics Week’ on Monday 18 November.

18 Nov 2013

New hope for patients whose melanoma has metastasised to the brain

New data show that in patients whose melanoma (BRAF V600 mutation-positive) has spread (metastasised) to the brain, Zelboraf (vemurafenib) extends life expectancy by over six months compared to chemotherapy.1 These results are welcome news for patients suffering from metastatic melanoma, as up to half of these patients are diagnosed with brain metastases with many given less than six months to live.1

18 Nov 2013

NPS MedicineWise urges all health professionals to preserve the miracle of antibiotics

Marking the start of Antibiotic Awareness Week, NPS MedicineWise is urging all health professionals to pledge their commitment to preserve the miracle of antibiotics and re-shape consumer expectations of these lifesavings medicines.

18 Nov 2013

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Eisai announces today that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals.

18 Nov 2013

Study suggests potential new treatment for seizures

A study out today in the journal Nature Medicine suggests a potential new treatment for the seizures that often plague children with genetic metabolic disorders and individuals undergoing liver failure. The discovery hinges on a new understanding of the complex molecular chain reaction that occurs when the brain is exposed to too much ammonia.

17 Nov 2013

Errors in medication common on admission to mental health services, shows study

A recent study, published in the International Journal of Clinical Pharmacy, involving Aston University (UK), South Essex Partnership University NHS Foundation Trust (SEPT) and the University of East Anglia (UK) found medication errors were common on admission to mental health services.

16 Nov 2013

Pharmaceutical News

Multiple sclerosis researchers receive NMSS drug development grant

Enhancing the NMDA glutamate receptor causes antidepressant-like effects

First look at The Endocrine Society's Performance-Enhancing Drugs Scientific Statement

Adverse events linked with HPV vaccine appear to be related with media coverage

Study finds resveratrol in colored vegetables, fruits may block effects of methamphetamine

mTOR protein: A key mediator of antidepressant effects of ketamine

UCP1 protein helps fight against obesity

U-M researchers collaborate with MDCH to evaluate statewide influenza vaccination reminder campaign

Long-term use of PDE3 inhibitors can lead to increased risk for sudden cardiac death

Treating traumatic brain-injured patients with anticoagulant decreases risk of dangerous clots

Research shows oral contraceptive use over three years could be a risk factor for glaucoma

Vismodegib drug does not offer added benefits for patients with BCC

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Entire structure of health-care delivery needs to be re-engineered to address threat of antibiotic resistance

New hope for patients whose melanoma has metastasised to the brain

NPS MedicineWise urges all health professionals to preserve the miracle of antibiotics

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Study suggests potential new treatment for seizures

Errors in medication common on admission to mental health services, shows study

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News